2025年上半年我国医药进出口贸易底盘稳固

Core Insights - In the first half of 2025, China's pharmaceutical import and export trade remained stable despite a complex external environment, with a total trade volume of $97.95 billion, a slight increase of 0.2% year-on-year [1] - Exports amounted to $54.54 billion, reflecting a year-on-year growth of 3.8%, while imports totaled $43.41 billion, showing a decline of 3.9% [1] Pharmaceutical Products Overview - The export of key pharmaceutical products such as raw materials, hospital diagnostics and treatments, disposable consumables, and Western medicine formulations continued to grow, with the main export markets, excluding the U.S., also seeing increases [1] - The decline in imports was primarily attributed to a significant drop in medical device imports across the board [1] Traditional Chinese Medicine (TCM) - The import and export volume of TCM products was $3.97 billion, down 4.6% year-on-year, with exports at $2.54 billion (down 4.3%) and imports at $1.43 billion (down 5.2%) [2] - Notable declines in export volumes were observed for key TCM products, with prices for TCM products decreasing by 23% year-on-year [2] - TCM imports showed a positive trend with a 14.9% increase, supported by favorable policies and the addition of 24 new importable TCM materials [2] Western Medicine - The import and export volume of Western medicine products remained stable, with exports at $27.93 billion (up 3.7%) and imports at $24.99 billion (down 3.9%) [3] - Raw material exports reached $27.93 billion, with a slight price decrease of 1.8%, while vitamin exports saw significant growth [3] - The export of Western medicine formulations grew by 6.5%, with notable increases in hormone and vitamin products [4] Medical Devices - Medical device exports totaled $24.1 billion, reflecting a 5% increase, while imports were $16.99 billion, down 3.9% [5] - Significant growth was noted in hospital diagnostics and treatment categories, with specific devices like artificial joints and non-invasive ventilators showing substantial increases [5][6] - However, the overall import of medical devices saw a decline, with notable drops in various categories including in vitro diagnostic reagents and X-ray equipment [6] Trade Partners and Market Dynamics - China's pharmaceutical trade involved over 190 countries, with the EU, the U.S., and ASEAN being the top three partners, accounting for 60.5% of total trade [7] - Trade with the EU and the U.S. saw declines, while trade with ASEAN and Belt and Road Initiative countries experienced growth [7][9] - The export to Belt and Road countries reached $20.77 billion, up 4.5%, indicating a growing acceptance and demand for Chinese pharmaceutical products in these markets [9] Emerging Markets - Exports to BRICS countries like Russia and Brazil showed significant growth, while imports from Latin America also increased [9] - The stability of traditional products combined with the exploration of emerging markets is becoming essential for the international development of the industry [9]